From the March 2014 issue of HealthCare Business News magazine
Consistent with the statement from ASTRO that suggests prostate patients referred for proton therapy should be in “prospective clinical trial or registry,” most prostate patients cancer patients currently being treated with proton therapy in the U.S. are in a clinical trial or a registry. Surely all prostate cancer patients deserve the opportunity to choose a therapy that causes fewer side effects during treatment and fewer adverse changes in their long-term lifestyles.
HCBN: Do you expect a high turn-out at NPC2014?
LA: Yes we do. Capacity is 250. We will get close to that. NPC2014 is the premier proton therapy event of the year. Anybody who wants to learn more about the advantages of proton therapy will have that opportunity. The best of the best in the proton community will be on hand.
HCBN: What will be some of the important topics at NPC2014?
LA: Attendees will certainly be interested to learn what Christopher Pericak has to say about the state of the proton therapy marketplace in today’s health care reform climate. Proton pioneer Dr. James Cox will kick off the conference with a keynote speech about “where we are headed.” Dr. Elise Berliner, from the U.S. federal agency on health research and quality, will address patient registries. Additionally, the economics of proton therapy, planning, developing and launching a proton center, innovations in design, equipment and engineering, plus treating breast, head and neck cancers, and more will be featured.
Another highlight will be the announcement of the results of a 2014 NAPT/Dobson DaVanzo report on an in-depth “quality of life” survey of nearly 4,000 prostate patients reated with proton therapy at multiple centers across the U.S.
Back to HCB News
